Method for screening 2019-coronavirus and pre-judging severe pneumonia by double indexes

A coronavirus, a new type of technology, applied in the field of immune detection, can solve the problems of inability to effectively distinguish patients, no reports of successful development of IgA detection kits, increase in detection values, etc., and achieve the effect of solving insufficient medical conditions.

Active Publication Date: 2020-07-03
GUANGZHOU KANGRUN BIOTECHNOLOGY CO LTD +1
View PDF4 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The detection rate of nucleic acid detection reagents for new coronary pneumonia is low, and the sensitivity is only 30-50%, which cannot meet the needs of screening out all patients
[0005] The detection of total antibodies improves the sensitivity but cannot effectively distinguish which stage the patient is in and whether they are still infectious
The colloidal gold method is simple and fast, but the accuracy is not enough
The sensitivity and specificity of IgM and IgG antibodies measured by chemiluminescence method are both high, but the window period of the two is relatively long. IgM should be detected 3-5 days after the onset of the disease, and IgG can only be diagnosed after the detection value in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for screening 2019-coronavirus and pre-judging severe pneumonia by double indexes
  • Method for screening 2019-coronavirus and pre-judging severe pneumonia by double indexes
  • Method for screening 2019-coronavirus and pre-judging severe pneumonia by double indexes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] A detection reagent for detecting the novel coronavirus SARS-CoV-2 IgA antibody in the blood and detecting the sialoligated sugar chain antigen KL-6, which is used for screening novel coronavirus infection pneumonia, especially early screening novel coronavirus infection pneumonia, and The use of detection reagents for predicting severe patients.

[0037] Among them, severe patients are those with lung injury or fibrosis. When a severe patient is detected, it is generally reminded that the patient needs to seek medical treatment in a hospital, which provides the patient with an accurate basis for seeking medical treatment.

[0038] The detection reagent can detect the new coronavirus SARS-CoV-2 IgA antibody and sialoligated sugar chain antigen KL-6 in serum, plasma and whole blood.

[0039] The reagent of the present invention can simultaneously detect the novel coronavirus SARS-CoV-2 IgA antibody and the sialoglycosylated sugar chain antigen KL-6 in the blood, and can...

Embodiment 2

[0041] A detection reagent, which contains a detection reagent for detecting the new coronavirus SARS-CoV-2 IgA antibody in blood and a detection reagent for detecting the sialoligated sugar chain antigen KL-6, is used for early screening of new coronavirus infection pneumonia, and A kit for predicting severe patients. Among them, severe patients are those with lung injury or fibrosis. When a severe patient is detected, it is generally reminded that the patient needs to seek medical treatment in a hospital, which provides the patient with an accurate basis for seeking medical treatment. Among them, the detection reagent can detect the new coronavirus SARS-CoV-2 IgA antibody and the sialoligated sugar chain antigen KL-6 in serum, plasma and whole blood.

[0042] The kit contains test card, sample diluent, pipette, etc.

[0043] Test card, the test card is composed of SARS-CoV-2 IgA test strips, KL-6 test strips and plastic box, each test strip contains nitrocellulose membrane...

Embodiment 3

[0080] Using N protein as a kit for magnetic bead-coated antigens to detect 12 normal human sera, 5 mild cases and 5 severe cases of new coronary pneumonia patients with onset of 2-8 days as an example, the detection operation process is as follows:

[0081] 1. Equilibrate the samples to be tested, test reagents and other test materials to room temperature before testing, and the test should be carried out at room temperature. Note: Room temperature refers to a temperature of 10°C to 30°C and a humidity of 45% to 75%.

[0082] 2. Unscrew the dropper of the dropper, draw the sample to be tested with a straw, add a drop of the sample to be tested into the dropper for dilution (1:10 dilution), tighten the dripper, shake up and down, and mix well.

[0083] 3. Tear open along the incision of the aluminum foil bag, take out the test card and place it flat on the table (note: do not touch the surface of the interlayer film of the test strip with your fingers).

[0084] 4. Open the b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are a detection reagent and a kit. The reagent detects a 2019-coronavirus SARS-CoV-2 immunoglobulin A (SARS-CoV-2 IgA) antibody in blood and a salivary liquefied sugar chain antigen KL-6 at the same time, and is used for screening, especially for early screening of 2019-coronavirus infected pneumonia, and for pre-judging the detection reagent for severe patients. The kit comprises a testcard, and the test card is composed of an SARS-CoV-2 IgA test strip, a KL-6 test strip and a plastic box. The reagent and the kit disclosed by the invention can be used for diagnosing the new coronavirus pneumonia at an earlier stage and can be used for judging whether a patient suffering from the new coronavirus pneumonia has lung injury or not.

Description

technical field [0001] The invention relates to the technical field of immunoassay, in particular to a simultaneous detection of novel coronavirus SARS-CoV-2 IgA antibody and sialoligated sugar chain antigen KL-6 in blood for screening, especially early screening of novel coronavirus infection Pneumonia, and detection reagents and kits for predicting severe patients and their uses. Background technique [0002] As an acute respiratory infectious disease, novel coronavirus-infected pneumonia (COVID-19) has been included in the Class B infectious disease stipulated in the "Law of the People's Republic of China on the Prevention and Control of Infectious Diseases", and is managed as a Class A infectious disease. COVID-19 usually develops within 3-7 days after infection with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Symptoms include fever, dry cough, and fatigue, and may also be accompanied by nasal congestion, runny nose, sore throat, myalgia, and diarrhea. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N33/58G01N33/577G01N33/569G01N33/558
CPCG01N33/558G01N33/56983G01N33/577G01N33/587G01N33/6854G01N2333/165G01N2469/10G01N2469/20
Inventor 孙宝清黄文喜徐永仲胡洪海何伟皇林琴
Owner GUANGZHOU KANGRUN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap